Ambrx Biopharma, Inc.

10975 North Torrey Pines Road

La Jolla, CA 92037

November 1, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Joshua Gorsky

 

Re:	Ambrx Biopharma, Inc.

Registration Statement on Form S-3

File No. 333-275053

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ambrx Biopharma, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 5:30 p.m., Eastern Time, on November 2, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective.

Please contact Gregg Noel, of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at (650) 470-4540, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.